<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04443010</url>
  </required_header>
  <id_info>
    <org_study_id>PH-L19TNFTMZ-01/20</org_study_id>
    <nct_id>NCT04443010</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma</brief_title>
  <acronym>GLIOSUN</acronym>
  <official_title>A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Standard Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philogen S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philogen S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety profile and establish a recommended dose&#xD;
      (RD) for phase II of the antibody-cytokine fusion protein L19TNF plus standard TMZ&#xD;
      chemoradiotherapy in patients with newly diagnosed glioblastoma.&#xD;
&#xD;
      The study will be conducted in three consecutive parts: a dose finding part to determine the&#xD;
      RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that&#xD;
      investigates first signs of activity and then an activity evaluation part that studies the&#xD;
      efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open label phase I/II study in subjects with newly diagnosed glioblastoma. The study will be conducted in three consecutive parts: (i) first the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, (ii) followed by a signal seeking part that investigates first signs of activity and (iii) then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For Phase 1: DLT</measure>
    <time_frame>For Cohort 1 and Cohort 2 from Day 1 to Day 28 of the maintenance cycle; for Cohort 3, 4 and 5 from Day 1 to Day 42 of the chemoradiotherapy.</time_frame>
    <description>Occurrence of dose limiting toxicity (DLT) assessed by frequency and grade of adverse events (AE) according to CTCAE v.5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For Phase 2: Overall Survival</measure>
    <time_frame>From beginning of treatment to 52 weeks</time_frame>
    <description>Overall survival (OS) rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From the date of enrollment to the date of progression or death for any cause, whichever came first, assessed up to 58 weeks</time_frame>
    <description>Progression Free Survival (PFS) will be assessed for all enrolled subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR in CR</measure>
    <time_frame>At week 10, at week 22, at week 34, at week 46 and at week 58</time_frame>
    <description>Objective Response Rate (ORR): ORR is defined as the rate of patients with complete response (CR) (defined according to iRANO criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR in PR</measure>
    <time_frame>At week 10, at week 22, at week 34, at week 46 and at week 58</time_frame>
    <description>Objective Response Rate (ORR): ORR is defined as the rate of patients with partial response (PR) (defined according to iRANO criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR in CR</measure>
    <time_frame>At week 10, at week 22, at week 34, at week 46 and at week 58</time_frame>
    <description>Disease Control Rate (DCR) is defined as the rate of patients with complete response (CR) (defined according to iRANO criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR in PR</measure>
    <time_frame>At week 10, at week 22, at week 34, at week 46 and at week 58</time_frame>
    <description>Disease Control Rate (DCR) is defined as the rate of patients with partial response (PR) (defined according to iRANO criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR in SD</measure>
    <time_frame>At week 10, at week 22, at week 34, at week 46 and at week 58</time_frame>
    <description>Disease Control Rate (DCR) is defined as the rate of patients with stable disease (SD) (defined according to iRANO criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BORR in CR</measure>
    <time_frame>From date of enrollment to week 58</time_frame>
    <description>Considering the best observed response for any subject, Best Overall Response Rate (BORR) is defined as the rate of complete response (CR) (defined according to iRANO criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BORR in PR</measure>
    <time_frame>From date of enrollment to week 58</time_frame>
    <description>Considering the best observed response for any subject, Best Overall Response Rate (BORR) is defined as the rate of partial response (PR) (defined according to iRANO criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BORR in SD</measure>
    <time_frame>From date of enrollment to week 58</time_frame>
    <description>BConsidering the best observed response for any subject, Best Overall Response Rate (BORR) is defined as the rate of stable disease (SD) (defined according to iRANO criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (AE)</measure>
    <time_frame>Throughout study completion for each patient, a maximum of 58 weeks for each patient</time_frame>
    <description>Safety of administration of L19TNF, through an assessed by Common Toxicity Criteria (version 5.0, CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (SAE)</measure>
    <time_frame>Throughout study completion for each patient, a maximum of 58 weeks for each patient</time_frame>
    <description>Safety of administration of L19TNF, assessed by Common Toxicity Criteria (version 5.0, CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (DILI)</measure>
    <time_frame>Throughout study completion for each patient, a maximum of 58 weeks for each patient</time_frame>
    <description>Evaluation of possible Drug Induce Liver Injury, caused by L19TNF, assessed by Common Toxicity Criteria (version 5.0, CTCAE)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Phase 1 part: Dose Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated in cohorts according to a 3+3 study design with standard treatment (consisting of radiotherapy of 60 Gy/30 fractions for 6 weeks plus 75 mg/m2 TMZ (temozolomide) daily (chemoradiotherapy), followed by 4 weeks of treatment break, followed by maintenance treatment with 6 maintenance cycles of TMZ 150-200 mg/m2 on Days 1 to 5 q28) combined with L19TNF at different dose levels on Day 1, 3, 5, 22, 24 and 26 of chemoradiotherapy and on Day 1, 3 and 5 of each 28-day chemotherapy maintenance cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 part: Signal Seeking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 patients will receive standard chemoradiotherapy and L19TNF at RD and with the administration scheme established in phase I part of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2b part: Activity Evaluation_control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).&#xD;
- Arm 2: Patients will receive radiotherapy and TMZ (temozolomide).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase IIb part: Activity Evaluation_treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).&#xD;
- Arm 1: Patients will receive radiotherapy, TMZ (temozolomide) and L19TNF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onfekafusp alfa</intervention_name>
    <description>This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.&#xD;
The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.</description>
    <arm_group_label>Phase 1 part: Dose Finding</arm_group_label>
    <arm_group_label>Phase 2 part: Signal Seeking</arm_group_label>
    <arm_group_label>Phase IIb part: Activity Evaluation_treatment arm</arm_group_label>
    <other_name>L19TNF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma</description>
    <arm_group_label>Phase 2b part: Activity Evaluation_control arm</arm_group_label>
    <arm_group_label>Phase IIb part: Activity Evaluation_treatment arm</arm_group_label>
    <other_name>TMZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age ≥18.&#xD;
&#xD;
          2. Patients with histologically confirmed newly diagnosed glioblastoma.&#xD;
&#xD;
          3. Karnofsky Performance Score (KPS) ≥ 70%&#xD;
&#xD;
          4. Documented negative test for HIV-HBV-HCV. For HBV serology, the determination of HBsAg&#xD;
             and anti-HBcAg Ab is required. In patients with serology documenting previous exposure&#xD;
             to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative&#xD;
             serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects&#xD;
             with a positive test for HCV antibody but no detection of HCV-RNA indicating no&#xD;
             current infection are eligible.&#xD;
&#xD;
          5. Female patients: negative pregnancy test for women of childbearing potential (WOCBP)*&#xD;
             within 14 days of starting treatment. WOCBP must agree to use, from the screening to 6&#xD;
             months following the last study drug administration, highly effective contraception&#xD;
             methods, as defined by the &quot;Recommendations for contraception and pregnancy testing in&#xD;
             clinical trials&quot; issued by the Head of Medicine Agencies' Clinical Trial Facilitation&#xD;
             Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or&#xD;
             combined (estrogen- and progesterone-containing) hormonal contraception associated&#xD;
             with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing&#xD;
             systems, bilateral tubal occlusion or vasectomized partner.&#xD;
&#xD;
          6. Male patients: male subjects able to father children must agree to use two acceptable&#xD;
             methods of contraception throughout the study (e.g. condom with spermicidal gel).&#xD;
             Double-barrier contraception is required.&#xD;
&#xD;
          7. Personally signed and dated informed consent document indicating that the subject has&#xD;
             been informed of all pertinent aspects of the study.&#xD;
&#xD;
          8. Willingness and ability to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests and other study procedures.&#xD;
&#xD;
               -  Women of childbearing potential are defined as females who have experienced&#xD;
                  menarche, are not postmenopausal (12 months with no menses without an alternative&#xD;
                  medical cause) and are not permanently sterilized (e.g., tubal occlusion,&#xD;
                  hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment for glioma, except surgery.&#xD;
&#xD;
          2. Inability to undergo contrast-enhanced MRI.&#xD;
&#xD;
          3. Intent to be treated with tumor-treating fields prior to progression.&#xD;
&#xD;
          4. Known history of allergy to TNF or TMZ, any excipient in the study medication or any&#xD;
             other intravenously administered human proteins/peptides/antibodies.&#xD;
&#xD;
          5. Absolute neutrophil count (ANC) &lt; 1.5 x 10^9/L, platelets &lt; 100 x 10^9/L or&#xD;
             haemoglobin (Hb) &lt; 9.0 g/dl.&#xD;
&#xD;
          6. Chronically impaired renal function as indicated by creatinine clearance &lt; 60 mL/min&#xD;
             or serum creatinine &gt; 1.5 ULN.&#xD;
&#xD;
          7. Inadequate liver function (ALT, AST, ALP ≥ 2.5 x ULN or total bilirubin ≥ 2.0 x ULN).&#xD;
&#xD;
          8. INR &gt; 1.5 ULN.&#xD;
&#xD;
          9. Any severe concomitant condition which makes it undesirable for the patient to&#xD;
             participate in the study or which could jeopardize compliance with the protocol, in&#xD;
             the opinion of the investigator.&#xD;
&#xD;
         10. Active or history of autoimmune disease that might deteriorate when receiving an&#xD;
             immuno-stimulatory agent.&#xD;
&#xD;
         11. History within the last year of cerebrovascular disease and/or acute or subacute&#xD;
             coronary syndromes including myocardial infarction, unstable or severe stable angina&#xD;
             pectoris.&#xD;
&#xD;
         12. Heart insufficiency (&gt; Grade II, New York Heart Association (NYHA) criteria).&#xD;
&#xD;
         13. Clinically significant cardiac arrhythmias or requiring permanent medication.&#xD;
&#xD;
         14. Abnormal LVEF or any other abnormalities observed during baseline ECG and&#xD;
             echocardiogram investigations that are considered as clinically significant by the&#xD;
             investigator. Subjects with current or a history of QT/QTc prolongation are excluded.&#xD;
&#xD;
         15. Uncontrolled hypertension.&#xD;
&#xD;
         16. Known arterial aneurism at high risk of rupture.&#xD;
&#xD;
         17. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine&#xD;
             classification).&#xD;
&#xD;
         18. Medically documented history of or active major depressive episode, bipolar disorder&#xD;
             (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt&#xD;
             or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or&#xD;
             patients with active severe personality disorders.&#xD;
&#xD;
         19. Anxiety ≥ CTCAE Grade 3.&#xD;
&#xD;
         20. Severe diabetic retinopathy such as severe non-proliferative retinopathy and&#xD;
             proliferative retinopathy.&#xD;
&#xD;
         21. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery)&#xD;
             within 3 weeks of administration of study treatment.&#xD;
&#xD;
         22. Known history of tuberculosis.&#xD;
&#xD;
         23. Pregnancy or breast feeding.&#xD;
&#xD;
         24. Requirement of chronic administration of high dose corticosteroids or other&#xD;
             immunosuppressant drugs. Subjects must have been either off corticosteroids, or on a&#xD;
             stable or decreasing dose ≤ 4 mg daily dexamethasone (or equivalent) for 7 days prior&#xD;
             to start of chemoradiotherapy. Limited or occasional use of corticosteroids to treat&#xD;
             or prevent acute adverse reactions is not considered an exclusion criterion.&#xD;
&#xD;
         25. Presence of active and uncontrolled infections or other severe concurrent disease,&#xD;
             which, in the opinion of the investigator, would place the patient at undue risk or&#xD;
             interfere with the study.&#xD;
&#xD;
         26. Concurrent malignancies unless the patient has been disease-free without intervention&#xD;
             for at least 2 years.&#xD;
&#xD;
         27. Growth factors or immunomodulatory agents within 7 days prior to the administration of&#xD;
             study treatment.&#xD;
&#xD;
         28. Serious, non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
         29. Requirement of concurrent therapy with anticoagulants at therapeutic doses.&#xD;
&#xD;
         30. Requirement of concurrent use of other anti-cancer treatments or agents other than&#xD;
             study medication.&#xD;
&#xD;
         31. Any recent live vaccination within 4 weeks prior to treatment or plan to receive&#xD;
             vaccination during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Weiss, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatspital Zurich - Klinik fur Neurologie &amp; Hirntumorzentrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa Hemmerle, PhD</last_name>
    <phone>+390577017816</phone>
    <email>regulatory@philogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Serena Bettarini, Pharmacist</last_name>
    <phone>+390577017816</phone>
    <email>regulatory@philogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UniversitatSpital USZ</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Weiss, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>April 7, 2022</last_update_submitted>
  <last_update_submitted_qc>April 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04443010
org study id: PH-L19TNFTMZ-01/20
nct id: NCT04443010
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The purpose of this study is to explore the safety profile and establish a recommended dose
      (RD) for phase II of the antibody-cytokine fusion protein L19TNF plus standard TMZ
      chemoradiotherapy in patients with newly diagnosed glioblastoma.

      The study will be conducted in three consecutive parts: a dose finding part to determine the
      RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that
      investigates first signs of activity and then an activity evaluation part that studies the
      efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.
allocation: Non-Randomized
intervention model: Sequential Assignment
intervention model description: Open label phase I/II study in subjects with newly diagnosed glioblastoma. The study will be conducted in three consecutive parts: (i) first the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, (ii) followed by a signal seeking part that investigates first signs of activity and (iii) then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.
primary purpose: Treatment
masking: None (Open Label)
measure: For Phase 1: DLT
time frame: For Cohort 1 and Cohort 2 from Day 1 to Day 28 of the maintenance cycle; for Cohort 3, 4 and 5 from Day 1 to Day 42 of the chemoradiotherapy.
description: Occurrence of dose limiting toxicity (DLT) assessed by frequency and grade of adverse events (AE) according to CTCAE v.5.0.
measure: For Phase 2: Overall Survival
time frame: From beginning of treatment to 52 weeks
description: Overall survival (OS) rate
measure: PFS
time frame: From the date of enrollment to the date of progression or death for any cause, whichever came first, assessed up to 58 weeks
description: Progression Free Survival (PFS) will be assessed for all enrolled subjects.
measure: ORR in CR
time frame: At week 10, at week 22, at week 34, at week 46 and at week 58
description: Objective Response Rate (ORR): ORR is defined as the rate of patients with complete response (CR) (defined according to iRANO criteria)
measure: ORR in PR
time frame: At week 10, at week 22, at week 34, at week 46 and at week 58
description: Objective Response Rate (ORR): ORR is defined as the rate of patients with partial response (PR) (defined according to iRANO criteria)
measure: DCR in CR
time frame: At week 10, at week 22, at week 34, at week 46 and at week 58
description: Disease Control Rate (DCR) is defined as the rate of patients with complete response (CR) (defined according to iRANO criteria)
measure: DCR in PR
time frame: At week 10, at week 22, at week 34, at week 46 and at week 58
description: Disease Control Rate (DCR) is defined as the rate of patients with partial response (PR) (defined according to iRANO criteria)
measure: DCR in SD
time frame: At week 10, at week 22, at week 34, at week 46 and at week 58
description: Disease Control Rate (DCR) is defined as the rate of patients with stable disease (SD) (defined according to iRANO criteria)
measure: BORR in CR
time frame: From date of enrollment to week 58
description: Considering the best observed response for any subject, Best Overall Response Rate (BORR) is defined as the rate of complete response (CR) (defined according to iRANO criteria)
measure: BORR in PR
time frame: From date of enrollment to week 58
description: Considering the best observed response for any subject, Best Overall Response Rate (BORR) is defined as the rate of partial response (PR) (defined according to iRANO criteria)
measure: BORR in SD
time frame: From date of enrollment to week 58
description: BConsidering the best observed response for any subject, Best Overall Response Rate (BORR) is defined as the rate of stable disease (SD) (defined according to iRANO criteria)
measure: Safety (AE)
time frame: Throughout study completion for each patient, a maximum of 58 weeks for each patient
description: Safety of administration of L19TNF, through an assessed by Common Toxicity Criteria (version 5.0, CTCAE)
measure: Safety (SAE)
time frame: Throughout study completion for each patient, a maximum of 58 weeks for each patient
description: Safety of administration of L19TNF, assessed by Common Toxicity Criteria (version 5.0, CTCAE)
measure: Safety (DILI)
time frame: Throughout study completion for each patient, a maximum of 58 weeks for each patient
description: Evaluation of possible Drug Induce Liver Injury, caused by L19TNF, assessed by Common Toxicity Criteria (version 5.0, CTCAE)
arm group label: Phase 1 part: Dose Finding
arm group type: Experimental
description: Patients will be treated in cohorts according to a 3+3 study design with standard treatment (consisting of radiotherapy of 60 Gy/30 fractions for 6 weeks plus 75 mg/m2 TMZ (temozolomide) daily (chemoradiotherapy), followed by 4 weeks of treatment break, followed by maintenance treatment with 6 maintenance cycles of TMZ 150-200 mg/m2 on Days 1 to 5 q28) combined with L19TNF at different dose levels on Day 1, 3, 5, 22, 24 and 26 of chemoradiotherapy and on Day 1, 3 and 5 of each 28-day chemotherapy maintenance cycle.
arm group label: Phase 2 part: Signal Seeking
arm group type: Experimental
description: 32 patients will receive standard chemoradiotherapy and L19TNF at RD and with the administration scheme established in phase I part of the study.
arm group label: Phase 2b part: Activity Evaluation_control arm
arm group type: Active Comparator
description: Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).
- Arm 2: Patients will receive radiotherapy and TMZ (temozolomide).
arm group label: Phase IIb part: Activity Evaluation_treatment arm
arm group type: Experimental
description: Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).
- Arm 1: Patients will receive radiotherapy, TMZ (temozolomide) and L19TNF.
intervention type: Drug
intervention name: Onfekafusp alfa
description: This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.
The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.
arm group label: Phase 1 part: Dose Finding
arm group label: Phase 2 part: Signal Seeking
arm group label: Phase IIb part: Activity Evaluation_treatment arm
other name: L19TNF
intervention type: Drug
intervention name: Temozolomide
description: Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
arm group label: Phase 2b part: Activity Evaluation_control arm
arm group label: Phase IIb part: Activity Evaluation_treatment arm
other name: TMZ
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Tobias Weiss, PhD, MD
role: Principal Investigator
affiliation: Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum
last name: Teresa Hemmerle, PhD
phone: +390577017816
email: regulatory@philogen.com
last name: Serena Bettarini, Pharmacist
phone: +390577017816
email: regulatory@philogen.com
facility: 
status: Recruiting
contact: 
country: Switzerland
responsible party type: Sponsor
mesh term: Glioblastoma
mesh term: Temozolomide
sharing ipd: No